IMS Health Holdings (IMS Health Holdings) Research & Development : $0 Mil (TTM As of Jun. 2016)

View and export this data going back to 2014. Start your Free Trial

What is IMS Health Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. IMS Health Holdings's Research & Development for the three months ended in Jun. 2016 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2016 was $0 Mil.

IMS Health Holdings Research & Development Historical Data

The historical data trend for IMS Health Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMS Health Holdings Research & Development Chart

IMS Health Holdings Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Research & Development

Get a 7-Day Free Trial

IMS Health Holdings Quarterly Data
	Dec10	Dec11	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16
Research & Development	Get a 7-Day Free Trial												-	-	-	-	-

IMS Health Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

IMS Health Holdings (NYSE:IMS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

IMS Health Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of IMS Health Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

IMS Health Holdings (IMS Health Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » IMS Health Holdings Inc (NYSE:IMS) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.imshealth.com

IMS Health Holdings Inc was formed on October 23, 2009 in Delaware. The Company is an information and technology services company. It provides clients in the healthcare industry with comprehensive solutions to measure and improve their performance. It has collections of healthcare information, spanning sales, prescription and promotional data, medical claims, electronic medical records and social media. The Company provides service to healthcare organizations and decision makers around the world, spanning the breadth of life science companies, including pharmaceutical, biotechnology, consumer health and medical device manufacturers, as well as distributors, providers, payers, government agencies, policymakers, researchers and the financial community. The Company offers various information offerings developed to meet its clients' needs by using data secured from network of suppliers. The Company's offerings compete with various firms, including Accenture, Cognizant Technology Solutions, Covance, Deloitte, Evidera, GfK, Health Market Science, IBM, Infosys, inVentiv Health, Kantar Health, McKinsey, Nielsen, OptumInsight, Parexel, Press Ganey, Quintiles, RTI Health Solutions, Symphony Health Solutions, Synovate Healthcare, The Advisory Board, Trizetto, Verisk and ZS Associates. The Company has trademarks and service marks that it uses in connection with the operation of its business, including IMS Health, IMS, the IMS logo, IMS One, MIDAS, Xponent, DDD, AppScript, AppNucleus, MD360 Provider Performance Management and Evidence360.

Executives

Michael R Mcdonnell	officer: EVP and CFO	C/O IQVIA HOLDINGS INC., 83 WOOSTER HEIGHTS ROAD, DANBURY CT 06810
David Bonderman	other: Former 10% Owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Lgp Associates V Llc	director	11111 SANTA MONICA BLVD., SUITE 2000, LOS ANGELES CA 90025
Peridot Coinvest Manager Llc	director	11111 SANTA MONICA BOULEVARD, LOS ANGELES CA 90025
Green V Holdings, Llc	director	11111 SANTA MONICA BOULEVARD, SUITE 2000, LOS ANGELES CA 90025
Green Equity Investors V, L.p.	director	11111 SANTA MONICA BOULEVARD, SUITE 2000, LOS ANGELES CA 90025
Green Equity Investors Side V, L.p.	director	11111 SANTA MONICA BOULEVARD, SUITE 2000, LOS ANGELES CA 90025
Gei Capital V, Llc	director	11111 SANTA MONICA BOULEVARD, SUITE 2000, LOS ANGELES CA 90025
Sharad Mansukani	director	C/O AGILON HEALTH, INC., 6210 E HWY 290, SUITE 450, AUSTIN TX 78723
Lgp Management Inc	director	11111 SANTA MONICA BLVD, STE 2000, LOS ANGELES CA 90025
Leonard Green & Partners, L.p.	director	11111 SANTA MONICA BLVD, STE 2000, LOS ANGELES CA 90025
Jim Fasano	director	83 WOOSTER HEIGHTS, DANBURY CT 06810
Cpp Investment Board Private Holdings, Inc.	10 percent owner	ONE QUEEN STREET EAST,, SUITE 2500, TORONTO A6 M5C 2W5
Canada Pension Plan Investment Board	10 percent owner	ONE QUEEN STREET EAST, STE 2500, TORONTO ONTARIO A6 0000
Kevin C Knightly	officer: SVP, Information Offerings	1499 POST ROAD, FAIRFIELD CT 06824

IMS Health Holdings (IMS Health Holdings) Headlines

From GuruFocus

The Big 3: Larry Robbins' Top 2nd-Quarter Buys

By James Li James Li • 08-16-2016

Well-Known Companies Reach 52 Week Highs

By yifan900 yifan900 • 10-11-2016

Healthcare Informatics: A Value Investor's Perspective

By Thomas Macpherson Thomas Macpherson • 10-23-2015

5 Companies Reach 52-Week Highs

By yifan900 yifan900 • 02-13-2018

Weekly Insider Sells Highlight: IMS, NOW, BMY, EA

By James Xiao James Xiao • 08-11-2015